The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine

Journal of Viral Hepatitis

Volumn 13, Issue 6, 2006, Pages 415-425

  Gotto, J ^a   Webster, G J M ^a   Brown, D ^a   Jenkins, J ^b   Dusheiko, G M ^a   Bertoletti, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Antiviral treatment; HBV; Lamivudine; Steroid; Viral hepatitis; Virus specific CD8

Indexed keywords

CORTICOSTEROID; HEPATITIS B(E) ANTIGEN; HLA A2 ANTIGEN; LAMIVUDINE; PREDNISOLONE; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DESIGN; DRUG SPECIFICITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; TIME SERIES ANALYSIS; VIRUS INHIBITION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

ADULT; AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; DRUG THERAPY, COMBINATION; EPITOPES, T-LYMPHOCYTE; FEMALE; GLUCOCORTICOIDS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; PREDNISOLONE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 33745822477     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00716.x     Document Type: Article

References (29)

1. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
2. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770-774.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241.
4. Thimme R, Wieland S, Steiger C et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
5. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108.
6. Maini MK, Boni C, Ogg GS et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology 1999; 117: 1386-1396.
7. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442-3449.
8. Jung M, Spengler U, Schraut W et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 1991; 13: 310-317.
9. Webster GJ, Reignat S, Brown D et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-5719.
10. Reignat S, Webster GJ, Brown D et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002; 195: 1089-2101.
11. Perrillo RP. Short-term corticosteroid therapy in combination with lamivudine: a case of deja vu? Hepatology 2000; 32: 663-665.
12. Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987-991.
13. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32: 604-609.
14. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489-503.
15. Bertoni R, Sidney J, Fowler P, Chesnut R, Chisari F, Sette A. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 1997; 100: 503-513.
16. Boni C, Penna A, Ogg G et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B: new perspective for immune therapy. Hepatology 2001; 33: 963-971.
17. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595-605.
18. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295-301.
19. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000; 18: 309-345.
20. Riccardi C, Bruscoli S, Migliorati G. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacol Res 2002; 45: 361-368.
21. D'Adamio F, Zollo O, Moraca R et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997; 7: 803-812.
22. Cheng AL, Hsiung CA, Su IJ et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328.
23. Bertoletti A, Southwood S, Chesnut R et al. Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology 1997; 26: 1027-1034.
24. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci USA 2004; 101: 16004-16009.
25. Bocharov G, Ludewig B, Bertoletti A et al. Underwhelming the immune response: effect of slow virus growth on CD8(+)-T-lymphocyte responses. J Virol 2004; 78: 2247-2254.
26. Wodarz D, Nowak MA. Specific therapy regimes could lead to long-term immunological control of HIV. Proc Natl Acad Sci USA 1999; 96: 14464-14469.
27. Sprengers D, Janssen HL, Kwekkeboom J, Niesters HG, de Man RA, Schalm SW. In vivo immunization following virus suppression: a novel approach for inducing immune control in chronic hepatitis B. J Viral Hepat 2003; 10: 7-9.
28. Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT. J Viral Hepat 2004; 11: 552-558.
29. Webster G, Reignat S, Maini M et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanism. Hepatology 2000; 32: 1117-1124.